Insert Therapeutics treats first patient with nano-engineered anticancer therapeutic

By Elaine Rigoli

Tampa, Fla., July 19 - Arrowhead Research Corp. announced that its majority-owned subsidiary, Insert Therapeutics, has treated its first patient in a phase 1 study of IT-101, Insert's lead anticancer compound.

"The initiation of the clinical development phase for IT-101 is an important milestone for Insert Therapeutics. It demonstrates our commitment to bringing innovative therapies to the clinic that address significant, unmet patient needs," Insert chief scientific officer Thomas Schluep said in a news release.

The study is an open-label, dose-escalation phase 1 study in patients with inoperable or metastatic solid tumors and has been designed to evaluate the safety, tolerability and pharmacokinetics of IT-101.

Insert expects that between 24 and 48 patients will be enrolled in the study during its course.

Animal studies using IT-101 showed excellent anticancer activity, including complete remission of certain kinds of lung cancer, among others, the release said.

Insert Therapeutics commercializes delivery-enhanced therapeutics using a patented class of polymeric systems and is based in Pasadena, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.